Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP

Clinical Trials

Volumn 13, Issue 2, 2016, Pages 169-179

  Lazar, Ann A ^a,b   Bonetti, Marco ^c   Cole, Bernard F ^d   Yip, Wai Ki ^e,f   Gelber, Richard D ^e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOCCONI UNIVERSITY   (Italy)

^d Harvard TH Chan School of Public Health ^*  (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Biomarker; breast cancer; competing risk; interaction; overview; permutation based inference; personalized medicine; precision medicine; survival analysis

Indexed keywords

KI 67 ANTIGEN; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RECURRENCE; CELL SUBPOPULATION; HAZARD RATIO; HEALTH CARE; HUMAN; METHODOLOGY; NONPARAMETRIC TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; STATISTICAL ANALYSIS; SUBPOPULATION TREATMENT EFFECT PATTERN PLOT; BLOOD; BREAST NEOPLASMS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; OUTCOME ASSESSMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NITRILES; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 84960449984     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515609106     Document Type: Article

References (30)

1. Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Eng J Med 2007; 357: 2189-2194.
2. Kent DM, Rothwell PM, Ioannidis JPA, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2011; 11: 1-11.
3. Royston P, Altman D, Sauerbrei W,. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25: 127-141.
4. Wang SJ, O'Neil RT, Hung HJ,. Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials. Clin Trials 2010; 7: 525-536.
5. Lagakos SW,. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006; 354: 1667-1669.
6. Pocock S,. More on subgroup analysis in clinical trials. N Eng J Med 2008; 358: 2076-2077.
7. Bonetti M, Gelber RD,. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000; 19: 2595-2609.
8. Bonetti M, Gelber R,. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004; 5: 465-481.
9. Bonetti M, Zahrieh D, Cole BF, et al. A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data. Stat Med 2009; 28: 1255-1268.
10. Lazar AA, Cole BF, Bonetti M, et al. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. J Clin Oncol 2010; 28: 4539-4544.
11. Cui I, Hung HM, Wang SJ, et al. Issues related to subgroup analysis in clinical trials. J Biopharm Stat 2002; 12: 347-358.
12. Cox DR,. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol 1972; 34: 187-220.
13. The Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
14. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
15. Clahsen PC, van de Velde CJ, Duval C, et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 1999; 25: 356-363.
16. Miller WR, White S, Dixon JM, et al. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006; 94: 1051-1056.
17. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569-5575.
18. R Foundation for Statistical Computing. R: a language and environment for statistical computing (www.CRANR-project.org). Vienna: R Foundation for Statistical Computing, 2008.
19. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Kalbfleisch JD, Prentice RL,. The statistical analysis of failure time data. New York: Wiley, 1980, pp. 168-169.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
22. Cox DR,. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol 1972; 34: 187-220.
23. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
24. Potthoff RF, Peterson BL, George SL,. Detecting treatment-by-centre interactions in multi-centre clinical trials. Stat Med 2001; 30: 193-213.
25. Pocock S,. More on subgroup analysis in clinical trials. N Engl J Med 2008; 358: 2076.
26. Edgington ES,. Randomization tests. 3rd ed. New York: Marcel Dekker, 1995.
27. VanderWeele TJ, Knol MJ,. A tutorial on interaction. Epidemiol Method 2014; 3: 33-72.
28. Royston P, Sauerbrei W,. A new approach to modeling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004; 19: 2509-2525.
29. Simon R, Dixon DO, Freidlin BA,. A Bayesian model for evaluating specificity of treatment effects in clinical trials. Norwell, MA: Kluwer Academic Publications, 1995.
30. Simon R,. Bayesian subset analysis: application to studying treatment-by-gender interactions. Stat Med 2002; 21: 2909-2916.